

RECEIVED

SEP 28 2000

Claim 12, line 1, please delete "1," and insert --103,--.

Claim 16, line 2, please delete "and" and insert --,-- after Asthma;
line 3, please delete "and" and insert --or--.

Claim 19, line 2, delete "and/or C are" and insert in its place --is--.

103-124 SEP 28 2000/2300

B 3 38. (amended) A method of treating parasitic and bacterial infection in mammals by the administration of a therapeutic agent [containing venom and/or] comprising mammalian, plant or insect anti-serum reactive with Phospholipase A₂ enzymes.

Claim 58, line 1, please delete "method" and insert --formulation--.

Claim 59, line 1, please delete "method" and insert --formulation--.

Claim 60, line 1, please delete "method" and insert --formulation--;
line 1, please delete "6," and insert --105,--.

Claim 61, line 1, please delete "method" and insert --formulation--.

Claim 62, line 1, please delete "method" and insert --formulation--.

Claim 63, line 1, please delete "method" and insert --formulation--.

Claim 64, line 1, please delete "method" and insert --formulation--.

Claim 65, line 1, please delete "method" and insert --formulation--.

Claim 66, line 1, please delete "method" and insert --formulation--.

Claim 67, line 1, please delete "Therapeutic agents" and insert --A formulation--.

Claim 68, line 1, please delete "method" and insert --formulation--.

Claim 69, line 1, please delete "method" and insert --formulation--.

Claim 70, line 1, please delete "method" and insert --formulation--.

Claim 71, line 1, please delete "method" and insert --formulation--.

Claim 72, line 1, please delete "method" and insert --formulation--.

Please add new claims 103-124 as follows:

--103. A method as recited in claim 1, wherein said therapeutic agent further comprises

B 4/ venom.

104. A method according to claim 1, wherein said therapeutic agent further comprises Phospholipase C enzyme.

105. A pharmaceutical formulation as recited in claim 6, further comprising venom.

106. A method of treating neoplasm in a mammal in need of such treatment, comprising administering to said mammal a therapeutic agent comprising venom.

107. A method according to claim 106, wherein the administration is part of a combination therapy with other therapeutically effective agents.

108. A method according to claim 106, wherein the administration is in combination with adjuvants.

109. A method according to claim 106, wherein the venom is that of snake and/or insect.

By
110. A method according to claim 106, wherein the therapeutic agent is administered as an anti-inflammatory agent.

111. A method according to claim 106, wherein the therapeutic agent is administered to prevent immunosuppression.

112. A method according to claim 106, wherein the therapeutic agent is administered in the treating of allergic contact dermatitis, asthma, psoriasis or bronchitis.

113. A method according to claim 106, wherein said mammal is suffering from at least one condition selected from rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability resultant from enhanced production of

PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

114. A pharmaceutical formulation comprising venom and anti-serum to Phospholipase C enzyme or part thereof and/or at least one inhibitory compound to Phospholipase C for use as a therapeutic agent for the therapy of a neoplastic condition in a human or animal.

115. A pharmaceutical formulation according to claim 114, wherein the administration is part of a combination therapy with other therapeutically effective agents.

116. A pharmaceutical formulation according to claim 114, wherein the administration is in combination with adjuvants.

117. A pharmaceutical formulation according to claim 114, wherein the venom is that of snake and/or insect.

118. A pharmaceutical formulation according to claim 114, wherein the therapeutic agent is administered as an anti-inflammatory agent.
b4 w/

119. A pharmaceutical formulation according to claim 114, wherein the therapeutic agent is administered to prevent immunosuppression.

120. A pharmaceutical formulation according to claim 114, wherein the therapeutic agent is administered in the treating of allergic contact dermititis, asthma, psoriasis or bronchitis.

121. A pharmaceutical formulation according to claim 114, wherein said mammal is suffering from at least one condition selected from rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability resultant

from enhanced production of PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

122. A pharmaceutical formulation as recited in claim 114, wherein said at least one inhibitory compound to Phospholipase C is one or more of EDTA, phenanthroline, chloromercuribenzoic acid, iodoacetic acid, and 1-oleoyl-2-acetyl-sn-glycerol (OAG).

*By
at*
123. A method of treating parasitic and bacterial infection in mammals by the administration of a therapeutic agent comprising venom.

124. A method as recited in claim 123, wherein said parasite is an haemoflagellate parasite.

REMARKS

Claims 1-102 remain herein. New claims 102-124 are added hereby.

Below are responses to Restriction and Election of Species Requirements, in which the applicant has elected Group I. Some of the claims in this application included subject matter within Group I as well as subject matter outside Group I, as understood by the applicant. The above amendments are made to move non-elected subject matter from these claims into new claims.

In response to the Office Action mailed March 20, 2000, the Applicant provisionally elects Group I with traverse. Group I, as defined in the March 20, 2000 Office Action, is understood by the Applicant to encompass methods for treating or preventing diseases by administering anti-serum reactive with at least one phospholipase A₂ enzyme, as well as pharmaceutical formulations which contain such anti-serum. Based on this understanding, the Applicant believes that the entireties of the subject matter covered by each of claims 1 - 4, 6, 7, 10, 11, 13 - 25, 32, 35, 38 - 42, 58, 59, 61 - 73, 90 - 96 and 103 - 105 are within the elected group of subject matter.